March 31 Quick Takes: V-Bio, HealthQuad close venture funds
Plus CDMO Abzena raises $65M, Clovis meets in ovarian cancer, InflaRx misses in COVID, FDA updates COVID EUA guidance and more
Belgium-based V-Bio Ventures closed its second venture fund with €110 million ($120.5 million) to invest in therapeutics, other healthcare companies and agricultural bio start-ups. The firm had revealed a €78 million first close in February 2021. V-Bio frequently invests in technology emerging from VIB, the government-backed biotech research institute in Flanders, but the firm also expects to participate in syndicated deals in France, the Netherlands, Scandinavia, the U.K. and beyond. V-Bio’s 2016-vintage first fund closed at €76 million.
Indian healthcare VC HealthQuad said it held a final close at $162 million for HealthQuad Fund-II, which was oversubscribed by more than twice its original target. Investors in the fund included Merck & Co. Inc. (NYSE:MRK) and other global investors, including Ackermans & van Haaren, the Teachers Insurance and Annuity Association of America (TIAA), Quilvest, HCL Corp., Swedfund and the Small Industries Development Bank of India (SIDBI). The fund will invest in 10-15 healthcare companies in India, and has already invested in digital health, healthcare services and tech-enabled healthcare startup companies...